Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban

References

• Greinacher A. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2015;373:252–261. doi:10.1056/NEJMcp1411910.
   PubMed Web of Science ®Google Scholar
• Greinacher A, Pötzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71:247–251.
   PubMed Web of Science ®Google Scholar
• Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000;96:182–187.
   PubMed Web of Science ®Google Scholar
• Warkentin TE. Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. Thromb Haemost 2016;116:813–822. doi:10.1160/TH16-06-0435.
   PubMed Web of Science ®Google Scholar
• Warkentin T. HIT paradigms and paradoxes. J Thromb Haemost 2011;9:105–117. doi:10.1111/j.1538-7836.2011.04322.x.
   PubMed Web of Science ®Google Scholar
• Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, Linkins LA, Rodner SB, Selleng S, Warkentin TE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2018;2:3360–3392. doi:10.1182/bloodadvances.2018024489.
   PubMed Web of Science ®Google Scholar
• Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin‐induced thrombocytopenia. J Thromb Haemost 2017;15:2099–2114. doi:10.1111/jth.13813.
   PubMed Web of Science ®Google Scholar
• Padmanabhan A, Jones CG, Pechauer SM, Curtis BR, Bougie DW, Irani MS, Bryant BJ, Alperin JB, Deloughery TG, Mulvey KP, et al. IVIg for treatment of severe refractory heparin-induced thrombocytopenia. Chest 2017;152:478–485. doi:10.1016/j.chest.2017.03.050.
   PubMed Web of Science ®Google Scholar
• Arcinas LA, Manji RA, Hrymak C, Dao V, Sheppard JI, Warkentin TE. Autoimmune heparin‐induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin. Transfusion 2019;59:1924–1933. doi:10.1111/trf.15263.
   PubMed Web of Science ®Google Scholar
• Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med 2001;138:22–31. doi:10.1067/mlc.2001.115525.
   PubMed Web of Science ®Google Scholar
• Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol 1996;95:161–167. doi:10.1046/j.1365-2141.1996.d01-1876.x.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Arnold DM, Nazi I, Kelton JG. The platelet serotonin-release assay. Am J Hematol 2015;90:564–572. doi:10.1002/ajh.24006.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Pai M, Sheppard JI, Schulman S, Spyropoulos AC, Eikelboom JW. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost 2011;9:2389–2396. doi:10.1111/j.1538-7836.2011.04487.x.
   PubMed Web of Science ®Google Scholar
• Linkins LA, Hu G, Warkentin TE. Systematic review of fondaparinux for heparin‐induced thrombocytopenia: when there are no randomized controlled trials. Res Pract Thromb Haemost 2018;2:678–683. doi:10.1002/rth2.12145.
   PubMed Web of Science ®Google Scholar
• Shatzel JJ, Crapster-Pregont M, Deloughery TG. Non-vitamin K antagonist oral anticoagulants for heparin-induced thrombocytopenia. A systematic review of 54 reported cases. Thromb Haemost 2016;116:397–400. doi:10.1160/TH16-02-0101.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Pai M, Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood 2017;130:1104–1113. doi:10.1182/blood-2017-04-778993.
   PubMed Web of Science ®Google Scholar
• Tvito A, Bakchoul T, Rowe JM, Greinacher A, Ganzel C. Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment. Am J Hematol 2015;90:675–678. doi:10.1002/ajh.23971.
   PubMed Web of Science ®Google Scholar
• Poudel DR, Ghimire S, Dhital R, Forman DA, Warkentin TE Spontaneous HIT syndrome post-knee replacement surgery with delayed recovery of thrombocytopenia: a case report and literature review. Platelets 2017;28:614–620. doi:10.1080/09537104.2017.1366973.
   PubMed Web of Science ®Google Scholar
• Mian H, Warkentin TE, Sheppard JI, MacDonald A, Linkins LA, Benger A, Foley R. Autoimmune HIT due to apheresis catheter heparin flushes for stem cell harvesting before autotransplantation for myeloma. Blood 2017;130:1679–1682. doi:10.1182/blood-2017-06-788679.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Climans TH, Morin PA. Intravenous immune globulin to prevent heparin-induced thrombocytopenia. N Engl J Med 2018;378:1845–1848. doi:10.1056/NEJMc1801799.
   PubMed Web of Science ®Google Scholar
• Warkentin TE. High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Exp Rev Hematol 2019;12:685–698. doi:10.1080/17474086.2019.1636645.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Davidson BL, Büller HR, Gallus A, Gent M, Lensing AWA, Piovella F, Prins MH, Segers AEM, Kelton JG. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest 2011;140:366–373. doi:10.1378/chest.10-1599.
   PubMed Web of Science ®Google Scholar
• Warkentin TE. How I diagnose and manage HIT. Hematol Am Soc Hematol Educ Program 2011;2011:143–149. doi:10.1182/asheducation-2011.1.143.
   PubMedGoogle Scholar
• Schindewolf M, Steindl J, Beyer-Westendorf J, Schellong S, Dohmen PM, Brachmann J, Madlener K, Pötzsch B, Klamroth R, Hankowitz J, et al. Use of fondaparinux off-label or approved anticoagulants for management of heparin-induced thrombocytopenia. J Am Coll Cardiol 2017;70:2636–2648. doi:10.1016/j.jacc.2017.09.1099.
   PubMed Web of Science ®Google Scholar